150 related articles for article (PubMed ID: 34114181)
1. Neoadjuvant Chemoradiation Impacts the Prognostic Effect of Surgical Margin Status in Pancreatic Adenocarcinoma.
Zhang E; Wang L; Shaikh T; Handorf E; Wong JK; Hoffman JP; Reddy S; Cooper HS; Cohen SJ; Dotan E; Meyer JE
Ann Surg Oncol; 2022 Jan; 29(1):354-363. PubMed ID: 34114181
[TBL] [Abstract][Full Text] [Related]
2. Covered self-expandable metal stent deployment promises safe neoadjuvant chemoradiation therapy in patients with borderline resectable pancreatic head cancer.
Kubota K; Sato T; Watanabe S; Hosono K; Kobayashi N; Mori R; Taniguchi K; Matsuyama R; Endo I; Nakajima A
Dig Endosc; 2014 Jan; 26(1):77-86. PubMed ID: 23551230
[TBL] [Abstract][Full Text] [Related]
3. Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma.
Hu Q; Wang D; Chen Y; Li X; Cao P; Cao D
Radiat Oncol; 2019 Jul; 14(1):120. PubMed ID: 31291998
[TBL] [Abstract][Full Text] [Related]
4. Clinical Impact of Neoadjuvant Chemotherapy and Chemoradiotherapy in Borderline Resectable Pancreatic Cancer: Analysis of 884 Patients at Facilities Specializing in Pancreatic Surgery.
Nagakawa Y; Sahara Y; Hosokawa Y; Murakami Y; Yamaue H; Satoi S; Unno M; Isaji S; Endo I; Sho M; Fujii T; Takishita C; Hijikata Y; Suzuki S; Kawachi S; Katsumata K; Ohta T; Nagakawa T; Tsuchida A
Ann Surg Oncol; 2019 Jun; 26(6):1629-1636. PubMed ID: 30610555
[TBL] [Abstract][Full Text] [Related]
5. Survival after Margin-Positive Resection in the Era of Modern Chemotherapy for Pancreatic Cancer: Do Patients Still Benefit?
Arrington AK; Hsu CH; Schaefer KL; O'Grady CL; Khreiss M; Riall TS
J Am Coll Surg; 2021 Jul; 233(1):100-109. PubMed ID: 33781861
[TBL] [Abstract][Full Text] [Related]
6. Clinical benefits of neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreatic head: an observational study using inverse probability of treatment weighting.
Fujii T; Satoi S; Yamada S; Murotani K; Yanagimoto H; Takami H; Yamamoto T; Kanda M; Yamaki S; Hirooka S; Kon M; Kodera Y
J Gastroenterol; 2017 Jan; 52(1):81-93. PubMed ID: 27169844
[TBL] [Abstract][Full Text] [Related]
7. Intraoperative Pancreatic Neck Margin Assessment During Pancreaticoduodenectomy for Pancreatic Adenocarcinoma in the Era of Neoadjuvant Therapy: A Multi-institutional Analysis from the Central Pancreatic Consortium.
Kelly KN; Macedo FI; Seaton M; Wilson G; Hammill C; Martin RC; Maduekwe UN; Kim HJ; Maithel SK; Abbott DE; Ahmad SA; Kooby DA; Merchant NB; Datta J
Ann Surg Oncol; 2022 Sep; 29(9):6004-6012. PubMed ID: 35511392
[TBL] [Abstract][Full Text] [Related]
8. Inverse Probability of Treatment Weighting Analysis of Upfront Surgery Versus Neoadjuvant Chemoradiotherapy Followed by Surgery for Pancreatic Adenocarcinoma with Arterial Abutment.
Fujii T; Yamada S; Murotani K; Kanda M; Sugimoto H; Nakao A; Kodera Y
Medicine (Baltimore); 2015 Sep; 94(39):e1647. PubMed ID: 26426657
[TBL] [Abstract][Full Text] [Related]
9. Microscopic resection margin status in pancreatic ductal adenocarcinoma - A nationwide analysis.
Daamen LA; van Goor IWJM; Schouten TJ; Dorland G; van Roessel SR; Besselink MG; Bonsing BA; Bosscha K; Brosens LAA; Busch OR; van Dam RM; Fariña Sarasqueta A; Festen S; Groot Koerkamp B; van der Harst E; de Hingh IHJT; Intven MPW; Kazemier G; de Meijer VE; Nieuwenhuijs VB; Raicu GM; Roos D; Schreinemakers JMJ; Stommel MWJ; van Velthuysen MF; Verheij J; Verkooijen HM; van Santvoort HC; Molenaar IQ;
Eur J Surg Oncol; 2021 Mar; 47(3 Pt B):708-716. PubMed ID: 33323293
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant Treatment Versus Upfront Surgery in Resectable Pancreatic Cancer: A Cost-Effectiveness Analysis.
Arjani S; Prasath V; Suri N; Li S; Ahlawat S; Chokshi RJ
JCO Oncol Pract; 2023 Mar; 19(3):e439-e448. PubMed ID: 36548928
[TBL] [Abstract][Full Text] [Related]
11. Surgical results after preoperative chemoradiation therapy for patients with pancreatic cancer.
Satoi S; Yanagimoto H; Toyokawa H; Takahashi K; Matsui Y; Kitade H; Mergental H; Tanigawa N; Takai S; Kwon AH
Pancreas; 2009 Apr; 38(3):282-8. PubMed ID: 19142173
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcomes of pancreatic ductal adenocarcinoma resection following neoadjuvant chemoradiation therapy vs. chemotherapy.
Satoi S; Yanagimoto H; Yamamoto T; Ohe C; Miyasaka C; Uemura Y; Hirooka S; Yamaki S; Ryota H; Michiura T; Inoue K; Matsui Y; Tanigawa N; Kon M
Surg Today; 2017 Jan; 47(1):84-91. PubMed ID: 27262676
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant therapy affects margins and margins affect all: perioperative and survival outcomes in resected pancreatic adenocarcinoma.
de Geus SWL; Kasumova GG; Sachs TE; Ng SC; Kent TS; Moser AJ; Vahrmeijer AL; Callery MP; Tseng JF
HPB (Oxford); 2018 Jun; 20(6):573-581. PubMed ID: 29426635
[TBL] [Abstract][Full Text] [Related]
14. Comparative Effectiveness of Neoadjuvant Chemoradiation Versus Upfront Surgery in the Management of Recto-Sigmoid Junction Cancer.
Venigalla S; Chowdhry AK; Wojcieszynski AP; Lukens JN; Plastaras JP; Metz JM; Ben-Josef E; Mahmoud NN; Reiss KA; Shabason JE
Clin Colorectal Cancer; 2018 Sep; 17(3):e557-e568. PubMed ID: 29910004
[TBL] [Abstract][Full Text] [Related]
15. Treatment Utilization and Outcomes for Locally Advanced Rectal Cancer in Older Patients.
Nassoiy S; Christopher W; Marcus R; Keller J; Weiss J; Chang SC; Foshag L; Essner R; Fischer T; Goldfarb M
JAMA Surg; 2022 Nov; 157(11):e224456. PubMed ID: 36169964
[TBL] [Abstract][Full Text] [Related]
16. Survival after chemoradiation in resected pancreatic cancer: the impact of adjuvant gemcitabine.
Baschnagel A; Shah C; Margolis J; Nadeau L; Stein J; Jury R; Robertson JM
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):e331-5. PubMed ID: 22420967
[TBL] [Abstract][Full Text] [Related]
17. No Difference in Survival between Neo-Adjuvant Chemotherapy and Neo-Adjuvant Chemoradiation Therapy in Gastric Cardia Cancer Patients: A Contemporary View from the National Cancer Database.
Tsai C; Mueller A; Maubach J; Warschkow R; Nussbaum DP; Schmied BM; Blazer D; Gloor B; Worni M
Dig Surg; 2020; 37(3):249-257. PubMed ID: 31340206
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Impact of the Neutrophil-to-Lymphocyte Ratio in Borderline Resectable Pancreatic Ductal Adenocarcinoma Treated with Neoadjuvant Chemoradiotherapy Followed by Surgical Resection.
Kubo H; Murakami T; Matsuyama R; Yabushita Y; Tsuchiya N; Sawada Y; Homma Y; Kumamoto T; Endo I
World J Surg; 2019 Dec; 43(12):3153-3160. PubMed ID: 31549202
[TBL] [Abstract][Full Text] [Related]
19. Intraoperative Radiation Mitigates the Effect of Microscopically Positive Tumor Margins on Survival Among Pancreatic Adenocarcinoma Patients Treated with Neoadjuvant FOLFIRINOX and Chemoradiation.
Sekigami Y; Michelakos T; Fernandez-Del Castillo C; Kontos F; Qadan M; Wo JY; Harrison J; Deshpande V; Catalano O; Lillemoe KD; Hong TS; Ferrone CR
Ann Surg Oncol; 2021 Aug; 28(8):4592-4601. PubMed ID: 33393047
[TBL] [Abstract][Full Text] [Related]
20. Comparison of neoadjuvant chemotherapy versus upfront surgery with or without chemotherapy for patients with clinical stage III esophageal squamous cell carcinoma.
Matsuda S; Tsubosa Y; Sato H; Takebayashi K; Kawamorita K; Mori K; Niihara M; Tsushima T; Yokota T; Onozawa Y; Yasui H; Takeuchi H; Kitagawa Y
Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 26919154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
